Anzeige
Mehr »
Login
Freitag, 12.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
X-Leak: Jetzt der Mega-Meilenstein - Kurseskalation vorprogrammiert?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 917165 | ISIN: DK0015998017 | Ticker-Symbol: BV3
Tradegate
12.04.24
15:52 Uhr
20,490 Euro
-0,030
-0,15 %
1-Jahres-Chart
BAVARIAN NORDIC A/S Chart 1 Jahr
5-Tage-Chart
BAVARIAN NORDIC A/S 5-Tage-Chart
RealtimeGeldBriefZeit
20,03020,37020:31
20,08020,29020:31

Aktuelle News zur BAVARIAN NORDIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.04.Bavarian Nordic announces commercial availability of mpox vaccine in US379
02.04.Bavarian Nordic expands access to mpox vaccine in US71
02.04.Bavarian Nordic: Wichtige Mitteilung - so reagiert die Aktie259Bavarian Nordic hat am Dienstagmorgen die Markteinführung von JYNNEOS® in den Vereinigten Staaten angekündigt, einem Meilenstein, der die Präsenz des Unternehmens im Kampf gegen Mpox unterstreicht....
► Artikel lesen
02.04.Bavarian Nordic A/S: Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.164COPENHAGEN, Denmark, April 2, 2024 - Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant...
► Artikel lesen
21.03.Bavarian Nordic A/S - Notice Convening Annual General Meeting4
13.03.Bavarian Nordic A/S: Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland258COPENHAGEN, Denmark, March 13, 2024 - Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunization...
► Artikel lesen
12.03.Bavarian Nordic A/S: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such220COPENHAGEN, Denmark, March 12, 2024 - Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial...
► Artikel lesen
07.03.Earnings call: Bavarian Nordic posts record revenue, eyes growth in vaccines16
06.03.Bavarian Nordic A/S: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such9
06.03.Bavarian Nordic A/S: Bavarian Nordic Publishes Annual Report 2023701COPENHAGEN, Denmark, March 6, 2024 - Bavarian Nordic A/S. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: "Delivering our best-ever financial results in 2023, we are now...
► Artikel lesen
23.02.Bavarian Nordic's chikungunya vaccine secures EMA fast-track23
23.02.Bavarian Nordic gets swift EU review of chikungunya shot3
23.02.Bavarian Nordic Receives Accelerated Assessment With EMA For Chikungunya Vaccine Candidate8
23.02.Bavarian Nordic A/S: Bavarian Nordic's Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency569Accelerated assessment allows for a shorter review period with EMA.Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024. COPENHAGEN...
► Artikel lesen
22.02.Bavarian Nordic Hones Infectious Disease Focus by Dropping Cancer Vaccine R&D9
21.02.Bavarian Nordic pulls plug on cancer vaccine program9
21.02.Bavarian Nordic's revenue soars post-mpox outbreaks6
21.02.Bavarian Nordic terminates cancer vaccine work7
21.02.Bavarian Nordic ends cancer vaccine program to fully focus on profitable infectious disease range7
21.02.EXPRES2ION BIOTECHNOLOGIES: ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine9
Seite:  Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1